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The HLA-B27 gene is among the most studied
genes in the history of medicine, and its
relationship to ocular inflammation is well
established. In particular, it has been known
to be associated primarily with anterior chamber
inflammation with clinical manifestations of non-
granulomatous keratic precipitates, anterior
chamber cells and flare, and in some cases, fibrin
and/or hypopyon. With modern advanced imaging
technologies, posterior segment involvement,
including papillitis and retinal vasculitis can be
detected in up to 31% of patients with HLA-
B27-associated uveitis.[1] Moreover, wide-angle
imaging has allowed the diagnosis of peripheral
retinal vasculitis that may be missed by standard
imaging modalities.[2, 3]
Although the long-term visual prognosis of
HLA-B27-associated acute anterior uveitis (AAU)
is generally favorable,[4] patients with HLA-B27-
associated AAU are approximately five times
more likely to have a visual acuity of 20/200
or worse as compared to patients without HLA-
B27-positivity.[5] Suboptimal visual outcomes
may be complicated by steroid-induced side
effects or delay in treatment of refractory cases;
therefore, close monitoring with multimodality
imaging and employing a stepladder approach in
the management is necessary in every patient.
Unfortunately, since relatively few studies have
examined HLA-B27-associated AAU, and even
fewer have focused on refractory cases, HLA-B27-
associated AAU remains a significant therapeutic
challenge for uveitis specialists. In their well-written
manuscript and well-designed study published in
the current issue of Journal of Ophthalmic and
Vision Research (JOVR), Bajwa and colleagues[6]
contribute to the literature by discussing the
utility of infliximab in managing this particularly
challenging disease.
Recent prospective randomized controlled trials
have shown that intraocular inflammation can
be controlled in 57.1–66.7% of cases with first-
line immunomodulatory therapy (IMT) agents, such
as methotrexate and mycophenolate mofetil.[7]
Uveitis that involves the posterior segment may
not always respond to first-line IMT and at
time requires adjustment to second- or third-
line agents, including biologics or other steroid-
sparing agents. Infliximab and adalimumab are
the two most commonly used biologic agents
for noninfectious posterior uveitis (NIU). Unlike
adalimumab, infliximab has not been approved
by the FDA for NIU and is used off-label for
ocular inflammation. Data supporting the use of
infliximab in NIU stems largely from retrospective
and small prospective trials.[8–17] Infliximab can
be used as first-line therapy for certain systemic
diseases such as Adamantiades-Behçet disease[18]
and in cases of sight-threatening disease in
the setting of moderate to severe idiopathic
retinal vasculitis and optic disc inflammation,
or as a third-line therapy in uveitis refractory
to corticosteroids and conventional IMT. The
efficacy of infliximab is fairly rapid-onset, with
one study demonstrating 96% resolution of acute
inflammation one day after infusion,[19] which is
quite fast as compared to adalimumab, in which the
typical time to effectiveness typically ranges from 2
to 16 weeks.[20] These findings are consistent with
the study by Bajwa et al,[6] which demonstrated
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81.25% responsiveness after three months and
87.5% responsiveness after six months.
Some IMT agents, such as methotrexate and
mycophenolate mofetil, may take 8–12 weeks
before reaching maximum efficacy; adalimumab
takes a median of six weeks.[20] Therefore, three
months of follow-up is inadequate to determine
unresponsiveness. We typically follow our patient
in the clinics for six months or more to fully
assess drug efficacy and responsiveness. It
is important to continue therapy during this
time even if the disease is in stable condition
in order to achieve long-term quiescence and
remission. Adalimumab was FDA-approved for
the treatment of NIU after the completion of
two successful phase-3 multicenter randomized
controlled trials, VISUAL I and II, that investigated
the use of adalimumab strictly for intermediate,
posterior, or pan-uveitis.[21, 22] No specific data
regarding the percentage and subtypes of HLA-
B27-associated uveitis is available from the
VISUAL I and II studies. It is quite interesting that
many patients had refractory anterior uveitis in
the Bajwa study[6] prior to the study entry and
20.8% were considered to be unresponsive or
intolerant to adalimumab therapy. It would be
beneficial if Bajwa and colleagues could provide
information on prior immunosuppression treatment
regimens including route, time, and dosage.
Moreover, no clear definition of “unresponsive
inflammation” is provided. According to the study,
9.5–19% of patients experienced a flare up while
on treatment with infliximab, and one patient
developed vasculitis after 3 months of treatment
which remained active until 24months. We suspect
that the authors may be more in favor of infliximab
than other IMT agents, having kept the patient on
a similar treatment regimen.
In addition, the authors discuss antibody
formation against infliximab. It would be very
helpful to know whether testing for this antibody
was performed as well as how many patients
were on concurrent IMT (such as methotrexate or
mycophenolate) to prevent or decrease the risk of
antibody formation. In the Bajwa study,[6] treatment
was prematurely stopped in three patients, and
one patient still had active disease at the end of
24 months. The authors can speculate or suggest
what may be the next treatment option(s) for these
patients.
In summary, while infliximab is a robust
treatment, roughly 10–20% of patients may
not show an adequate response to therapy. These
patients may need augmentation with additional
therapeutic approaches. Recent emerging and
adopted therapies, including tocilizumab (STOP
study),[23] sarilumab (SATURN study),[24] and
sirolimus (SAVE-2 and SAKURA studies),[25–28]
have shown encouraging efficacy outcomes
with a relatively favorable safety profile. Other
clinical trials evaluating the safety and efficacy of
filgotinib,[29] tofacitinib,[30] and adrenocorticotropic
hormone[31] in NIU are currently in progress.
Amidst the current global COVID-19 pandemic,
one of the most common concerns we have
received from patients on IMT is whether their
treatment might increase the risk of worsening a
COVID-19 infection if they were to contract severe
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2). Currently, there is no clear evidence to
suggest that IMT for ocular diseases increases the
risk for infection or complications from COVID-
19. Although further studies are needed, perhaps
tocilizumab, which has recently been shown to
reduce risk of death in patients with severe
COVID-19 disease,[32, 33] can be considered as an
alternative treatment option for patients with NIU
who fail therapy with infliximab.
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